BIOGEN INC (BIIB) Stock Fundamental Analysis
USA - NASDAQ:BIIB - US09062X1037 - Common Stock
143 USD
+0.74 (+0.52%)
143 USD
0 (0%)
Taking everything into account, BIIB scores 5 out of 10 in our fundamental rating. BIIB was compared to 536 industry peers in the Biotechnology industry. BIIB scores excellent on profitability, but there are some minor concerns on its financial health. BIIB is cheap, but on the other hand it scores bad on growth. This makes BIIB very considerable for value investing!
1. Profitability
1.1 Basic Checks
BIIB had positive earnings in the past year.
In the past year BIIB had a positive cash flow from operations.
Each year in the past 5 years BIIB has been profitable.
BIIB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BIIB (5.40%) is better than 91.79% of its industry peers.
Looking at the Return On Equity, with a value of 8.68%, BIIB belongs to the top of the industry, outperforming 92.91% of the companies in the same industry.
BIIB has a better Return On Invested Capital (9.52%) than 94.22% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIIB is below the industry average of 15.49%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROIC | 9.52% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
Looking at the Profit Margin, with a value of 15.31%, BIIB belongs to the top of the industry, outperforming 93.66% of the companies in the same industry.
In the last couple of years the Profit Margin of BIIB has declined.
BIIB has a better Operating Margin (27.35%) than 96.27% of its industry peers.
BIIB's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 75.43%, BIIB belongs to the top of the industry, outperforming 83.58% of the companies in the same industry.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BIIB is creating some value.
BIIB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIIB has less shares outstanding
BIIB has a better debt/assets ratio than last year.
2.2 Solvency
BIIB has an Altman-Z score of 3.04. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
BIIB has a better Altman-Z score (3.04) than 69.40% of its industry peers.
BIIB has a debt to FCF ratio of 3.40. This is a good value and a sign of high solvency as BIIB would need 3.40 years to pay back of all of its debts.
BIIB's Debt to FCF ratio of 3.40 is amongst the best of the industry. BIIB outperforms 93.84% of its industry peers.
BIIB has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.36, BIIB is doing worse than 70.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Altman-Z | 3.04 |
ROIC/WACC1.06
WACC8.98%
2.3 Liquidity
BIIB has a Current Ratio of 2.50. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BIIB (2.50) is worse than 68.84% of its industry peers.
A Quick Ratio of 1.79 indicates that BIIB should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.79, BIIB is doing worse than 77.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
BIIB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.61%.
Measured over the past years, BIIB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
BIIB shows a small growth in Revenue. In the last year, the Revenue has grown by 3.36%.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
3.2 Future
Based on estimates for the next years, BIIB will show a small growth in Earnings Per Share. The EPS will grow by 1.15% on average per year.
BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.44% yearly.
EPS Next Y-1.72%
EPS Next 2Y-1.05%
EPS Next 3Y0.57%
EPS Next 5Y1.15%
Revenue Next Year0.4%
Revenue Next 2Y-1.8%
Revenue Next 3Y-1.14%
Revenue Next 5Y-0.44%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 8.93, the valuation of BIIB can be described as very reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.76% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.40, BIIB is valued rather cheaply.
The Price/Forward Earnings ratio is 8.87, which indicates a very decent valuation of BIIB.
97.95% of the companies in the same industry are more expensive than BIIB, based on the Price/Forward Earnings ratio.
BIIB is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.94, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.93 | ||
| Fwd PE | 8.87 |
4.2 Price Multiples
97.57% of the companies in the same industry are more expensive than BIIB, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIIB indicates a rather cheap valuation: BIIB is cheaper than 97.57% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.35 | ||
| EV/EBITDA | 7.01 |
4.3 Compensation for Growth
The decent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.05%
EPS Next 3Y0.57%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
143
+0.74 (+0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change0.16%
Ins Owners0.14%
Ins Owner Change3.4%
Market Cap20.97B
Analysts73.81
Price Target173.2 (21.12%)
Short Float %3.5%
Short Ratio3.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.1%
Min EPS beat(2)17.28%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)15.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)13.06%
EPS beat(12)12
Avg EPS beat(12)11.49%
EPS beat(16)14
Avg EPS beat(16)10.96%
Revenue beat(2)2
Avg Revenue beat(2)9.15%
Min Revenue beat(2)6.67%
Max Revenue beat(2)11.62%
Revenue beat(4)3
Avg Revenue beat(4)4.43%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)1.84%
Revenue beat(12)8
Avg Revenue beat(12)1.78%
Revenue beat(16)11
Avg Revenue beat(16)1.73%
PT rev (1m)0.78%
PT rev (3m)-0.08%
EPS NQ rev (1m)0.12%
EPS NQ rev (3m)-3.64%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)6.03%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)2.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.93 | ||
| Fwd PE | 8.87 | ||
| P/S | 2.1 | ||
| P/FCF | 11.35 | ||
| P/OCF | 9.9 | ||
| P/B | 1.19 | ||
| P/tB | 12.53 | ||
| EV/EBITDA | 7.01 |
EPS(TTM)16.01
EY11.2%
EPS(NY)16.13
Fwd EY11.28%
FCF(TTM)12.6
FCFY8.81%
OCF(TTM)14.44
OCFY10.1%
SpS68.19
BVpS120.28
TBVpS11.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROCE | 10.87% | ||
| ROIC | 9.52% | ||
| ROICexc | 10.7% | ||
| ROICexgc | 37.26% | ||
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% | ||
| FCFM | 18.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexcg growth 3Y14.15%
ROICexcg growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Debt/EBITDA | 1.81 | ||
| Cap/Depr | 36.28% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 60.86% | ||
| Profit Quality | 120.66% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 3.04 |
F-Score6
WACC8.98%
ROIC/WACC1.06
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
EPS Next Y-1.72%
EPS Next 2Y-1.05%
EPS Next 3Y0.57%
EPS Next 5Y1.15%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
Revenue Next Year0.4%
Revenue Next 2Y-1.8%
Revenue Next 3Y-1.14%
Revenue Next 5Y-0.44%
EBIT growth 1Y23.31%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y5.8%
FCF growth 1Y64.41%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y48.2%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%